Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)
Alexander D Sherry, Noah Meimoun, Avital M Miller, Jessica Liu, Kimi Chauhan, Ramez Kouzy, Timothy A Lin, Pavlos Msaouel, Ethan B Ludmir · 2026
Read Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA) by Alexander D Sherry, Noah Meimoun, Avital M Miller, Jessica Liu, Kimi Chauhan, Ramez Kouzy, Timothy A Lin, Pavlos Msaouel, Ethan B Ludmir (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13614714.txt.
Description
Alexander Sherry and eight colleagues present a 2026 meta-analysis with a blunt question for cancer research. When modern phase III trials aim at overall survival, how much do patients actually gain? Proving a survival benefit is expensive and slow, so trials often settle for stand-in endpoints of uncertain worth. The team rebuilt individual patient data from the published curves of qualifying trials.
One hundred fifty-nine trials covering over one hundred four thousand patients qualified. Patients randomized to experimental treatments lived longer, with a hazard ratio around zero point eight seven, a consistent thirteen percent cut in the risk of death. The authors argue the payoff is real and urge funders, regulators, and trialists to keep survival as the gold-standard endpoint.
Catalog record
| CREATOR | Alexander D Sherry, Noah Meimoun, Avital M Miller, Jessica Liu, Kimi Chauhan, Ramez Kouzy, Timothy A Lin, Pavlos Msaouel, Ethan B Ludmir |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |